TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8087820
Drug: Nitrates (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (intravenous, oral, or transdermal)
Study: 8087820
Drug: Nitrates (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (combined with lisinopril)
Study: 2832598
Drug: Continuous progestin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous progestin (2.5 mg daily)
Study: 2832598
Drug: Cyclic progestin
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic progestin (5 mg daily or 5 mg during the last 12 days of a 28-day cycle)
Study: 24398576
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (frequency of 50 Hz, amplitude of 2 mm, four 1-min series with 1-min rest intervals in three body positions)
Study: 23740686
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) 500 µg daily for 8 weeks
Study: 20646353
Drug: bLf 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: bLf 100 mg/twice/day
Study: 20646353
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 520 mg/day
Study: 8469455
Drug: Sequential vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential vacuum and forceps-assisted delivery
Study: 8469455
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of vacuum and forceps for assisted delivery
Study: 3780285
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of propranolol
Study: 27196818
Drug: Post-MRI ICD
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-MRI ICD sensing and treatment of ventricular tachyarrhythmias (VT/VF)
Study: 18426146
Drug: High-dose sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sublingual immunotherapy (SLIT) with a 6-grass pollen mixture, once daily for 2 years
Study: 16643482
Drug: Tolterodine extended-release
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended-release (ER) 4 mg once daily
Study: 10984368
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 microg once daily
Study: 10984368
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 200 microg twice daily
Study: 1453146
Drug: Clarithromycin, 250
Normalized name: Clarithromycin, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 250 mg twice daily
Study: 1453146
Drug: Penicillin VK,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin VK, 250 mg three times daily
Study: 6660217
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg guava juice (acute i.p. treatment)
Study: 6660217
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of guava juice
Study: 6660217
Drug: Chlorpropamide and
Normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide and metformin (control)
Study: 31536556
Drug: Everolimus (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (5-10 ng/mL) with mycophenolic acid (MPA) and basiliximab
Study: 29914943
Drug: Fluconazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (800 mg q24h) in combination with amphotericin B deoxycholate (1 mg/kg q24h)
Study: 29914943
Drug: Fluconazole (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (1,200 mg q24h)
Study: 29914943
Drug: Fluconazole monotherapy
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole monotherapy (from meta-analysis)
Study: 18307772
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g FFA PinnoThin
Study: 15756254
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of outpatient subcutaneous interleukin‐2 (sc‐rIL‐2), subcutaneous interferon‐alpha2a (sc‐rIFN‐alpha2a), and intravenous 5‐fluorouracil (iv‐5‐FU) according to the standard Atzpodien regimen
Study: 10065646
Drug: Simultaneous placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous placement of titanium implants
Study: 10065646
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of titanium implants
Study: 1699272
Drug: Iloprost (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (2 ng/kg/min, intravenously for 6 hours daily for 28 days)
Study: 19935461
Drug: Angiotensin‐II‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐II‐converting enzyme inhibitors or angiotensin II receptor blockers
Study: 12742466
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d sirolimus
Study: 12742466
Drug: 2 mg/d
Normalized name: Uceris, 2 mg/dose rectal foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/d sirolimus
Study: 9113932
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential therapy
Study: 8239913
Drug: Tołpa Torf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tołpa Torf Preparation (TTP) administered orally, 5 mg daily for three weeks
Study: 8239913
Drug: Tołpa Torf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tołpa Torf Preparation (TTP)
Study: 3104124
Drug: TTS NTG
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS NTG 40 cm2 (releasing 20 mg of NTG over 24 hours)
Study: 3104124
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg SR
Study: 3104124
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg SR
Study: 26205903
Drug: Protocol modifications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol modifications allowing for inclusion of patients receiving aspirin
Study: 18332071
Drug: TPA-based antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA-based antibiotic lock (ABL)
Study: 18332071
Drug: Heparin-based antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-based antibiotic lock (ABL)
Study: 6160353
Drug: N-allyl-clonidine (ST
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-allyl-clonidine (ST 567) 40 mg, i.v.
Study: 31374027
Drug: GnRH pulse
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH pulse therapy
Study: 31374027
Drug: HCG/HMG combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG/HMG combined treatment
Study: 23113645
Drug: SST using
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST using Ologen implant
Study: 19027977
Drug: Miglitol 150
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 150 mg/day
Study: 19027977
Drug: Mitiglinide 30
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 30 mg/day
Study: 16269646
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIIa (rFVIIa) administered intravenously within 4 hours of ICH onset
Study: 11975864
Drug: Cimicifugae racemosae
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifugae racemosae rhizoma (40 mg/day)
Study: 11975864
Drug: Cimicifugae racemosae
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifugae racemosae rhizoma (39 mg)
Study: 11975864
Drug: Cimicifugae racemosae
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifugae racemosae rhizoma (127.3 mg)
Study: 11975864
Drug: Cimicifugae racemosae
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifugae racemosae rhizoma (higher dose)
Study: 11975864
Drug: Cimicifugae racemosae
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifugae racemosae rhizoma (all doses)
Study: 7852113
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose total body irradiation (STBI)
Study: 7346530
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Slo-Phyllin Gyrocap
Study: 7346530
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Theo-dur tablet
Study: 31287046
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) of praziquantel, given annually or twice over 4 years
Study: 19333160
Drug: Opioid (oxycodone)
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid (oxycodone)
Study: 2673621
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day viqualine
Study: 2673621
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day viqualine
Study: 2673621
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of viqualine
Study: 10942
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 or 2 mg)
Study: 28046034
Drug: Daily notifications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily notifications within pre-defined time frames
Study: 22105724
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation with intravenous propofol administered by anesthesiologist
Study: 16227143
Drug: Diclofenac after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac after pre-treatment with bendroflumethiazide and enalapril
Study: 9813556
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (5‐20 ng/kg/min)
Study: 9813556
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (0.7‐2.8 micrograms/kg/min)
Study: 16025317
Drug: lormetazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam (1 mg)
Study: 21966064
Drug: zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: zopiclone (7.5 mg)
Study: 28002035
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplement for 12 weeks
Study: 28002035
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no omega-3 supplement)
Study: 23297557
Drug: Zhizhukuanzhong capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhukuanzhong capsules (ZZKZC)
Study: 23297557
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Electroacupuncture + ZZKZC)
Study: 23297557
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 mg mosapride three times daily and 20 mg pantoprazole twice daily)
Study: 18538974
Drug: New transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New transdermal fentanyl patch
Study: 18538974
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid treatment
Study: 11738537
Drug: haloperidol 12
Normalized name: haloperidol 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 12 mg/day
Study: 7876509
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (control)
Study: 2690165
Drug: Nefazodone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone therapy
Study: 24167166
Drug: Nonmedical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmedical prescription opiate use (NPOU)
Study: 24167166
Drug: Nonmedical prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmedical prescription sedative use (NPSU)
Study: 24167166
Drug: Current home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current home prescription for opioids
Study: 24167166
Drug: Current home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current home prescription for sedatives
Study: 24167166
Drug: Receiving an
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receiving an intravenous opioid in the ED
Study: 16943538
Drug: Reduced-dose craniospinal
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with lomustine (CCNU), cisplatin, and vincristine
Study: 16943538
Drug: Reduced-dose craniospinal
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with cyclophosphamide, cisplatin, and vincristine
Study: 25908603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as standard treatment)
Study: 1286488
Drug: Manidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine (10 to 40 mg daily for 12 months)
Study: 1286488
Drug: Delapril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril (15 to 60 mg daily for 12 months)
Study: 2408842
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg/d
Study: 2408842
Drug: Disopyramide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 600 mg/d
Study: 2408842
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg/d
Study: 29873953
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole 2 mg/d
Study: 21134044
Drug: onabotulinumtoxinA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: onabotulinumtoxinA plus 24‐mg/mL cohesive gel
Study: 21070457
Drug: 24‐mg/mL cohesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐mg/mL cohesive gel alone
Study: 12368933
Drug: Lisinopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (ACE inhibitor) for three days
Study: 382750
Drug: sulpiride (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulpiride (up to 1,800 mg per day)
Study: 382750
Drug: chlorpromazine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpromazine (up to 675 mg)
Study: 29508498
Drug: Locator-retained mandibular
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locator-retained mandibular overdentures with implants in the premolar areas (PM group)
Study: 29508498
Drug: Locator-retained mandibular
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locator-retained mandibular overdentures with implants in the canine regions (CA group)
Study: 23883812
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied three times daily for 30 days
Study: 21836471
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon α‐2b (1.5 μg/kg/wk) plus fixed ribavirin dose (800 mg/d) or weight‐based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks
Study: 16458458
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact once daily for 4 weeks
Study: 15548461
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment subgroups
Study: 10665554
Drug: pyrimethamine-sulphadoxine plus
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight)
Study: 10665554
Drug: pyrimethamine-sulphadoxine plus
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrimethamine-sulphadoxine plus three doses of artesunate (4 mg/kg bodyweight daily for 3 days)
Study: 9091006
Drug: Oestrogel (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogel (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Study: 9091006
Drug: Estreva (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estreva (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Study: 8374375
Drug: Glibenclamide regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide regimen 1: usual morning dose in the evening and evening dose before dawn
Study: 8374375
Drug: Glibenclamide regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide regimen 2: usual morning dose in the evening and evening dose before dawn with a reduction of total dose by a quarter
Study: 31786086
Drug: Additional ultrasound-accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional ultrasound-accelerated catheter-directed thrombolysis (urokinase with a starting bolus of 250,000 IU in 10 mL NaCl followed by 100,000 IU/h for a maximum of 96 h)
Study: 31786086
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (anticoagulant therapy, compression therapy, early ambulation)
Study: 28591675
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg)
Study: 23876463
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 54; target glucose 80-140 mg/dl)
Study: 23876463
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic control (CGC) (n = 52; target glucose 180-200 mg/dl)
Study: 21654268
Drug: Febuxostat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (all doses)
Study: 19261960
Drug: Subcutaneous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tramadol infiltration
Study: 19261960
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol administration
Study: 15310527
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin daily for 24 weeks
Study: 9412311
Drug: Vitamin B6,
Normalized name: Vitamin B6, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B6, 50 mg/d
Study: 9412311
Drug: Folic acid,
Normalized name: folic acid, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d
Study: 9412311
Drug: Vitamin B6,
Normalized name: Vitamin B6, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B6, 50 mg/d, folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d
Study: 3146370
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (100 mg over three hours)
Study: 30221006
Drug: Immediate-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release metformin 250 mg
Study: 30221006
Drug: Immediate-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release metformin 500 mg
Study: 30221006
Drug: Immediate-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release metformin 1000 mg
Study: 27406936
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (Gardasil)
Study: 19564902
Drug: Pralidoxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pralidoxime (2 g loading dose over 20 min, followed by 0.5 g/h for up to 7 days)
Study: 16724996
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (900 mg)
Study: 16724996
Drug: High-dose ulinastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ulinastatin (450,000 units)
Study: 16724996
Drug: Low-dose ulinastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ulinastatin (150,000 units)
Study: 14655042
Drug: Treatment outcomes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment outcomes
Study: 8487666
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (200 mg/wk intramuscularly)
Study: 8487666
Drug: Testolactone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testolactone (250 mg four times per day)
Study: 3232537
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (2 different doses)
Study: 3232537
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (test drug and placebo)
Study: 29298660
Drug: Fractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated stereotactic radiotherapy to the resection cavity (total dose of 46 Gy in 2 Gy per fraction or 36 Gy in 3 Gy per fraction)
Study: 24569129
Drug: QVA149 (440/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 (440/200 μg)
Study: 23699763
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (0.5 μg/kg/min for 4 hours)
Study: 18427133
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 to 10 mg) for 8 weeks
Study: 16048650
Drug: trimethoprim/sulfamethoxazole 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim/sulfamethoxazole 1 double-strength tablet twice daily for 3 days